diabzi sting agonist

diABZI STING agonist-1 (Tautomerism) (diABZI STING agonist (Compound 3)) is a selective agonist of the interferon gene-stimulated receptor (STING), with EC50 values of 130 nM in humans and 186 nM in mice. diABZI STING agonist-1 tautomerism is a tautomer of diABZI STING agonist-1. diABZI STING agonist-1 tautomerism can be used in research on tumor immunity, antiviral activity, and autoimmune diseases.

diABZI STING agonist-1 (trihydrochloride) is a stimulator of interferon genes (STING) receptor agonist.

diABZI STING agonist-1 is a selective and potent interferon gene-stimulating receptor (STING) agonist with potential antitumor and anti-inflammatory activity for the study of cancer.

diABZI-V/C-Mal is a modified STING agonist derivative based on the diABZI (di-amidobenzimidazole) scaffold. By directly binding to and activating the STING protein, diABZI-V/C-Mal induces the activation of immune-related signaling pathways such as type I interferon and is commonly used as a ligand for PROTAC target proteins.

Compound 3 (diABZI-V/C-DBCO) functions as an efficient STING agonist. This compound acts by releasing diABZI-amine under the action of cathepsin B to activate STING, thereby inducing the production of interferon and other immune-activating molecules, which enhances the immune system's response to tumors. In THP1-Dual cells, the EC50 values for STING activation by diABZI-V/C-DBCO and diABZI-amine are 1.47 nM and 0.144 nM, respectively, and in primary mouse splenic cells, the EC50 values are 7.7 µM and 0.17 µM, respectively. diABZI-V/C-DBCO is useful for research in the field of cancer immunotherapy.

DiABZI-4 is an orally active STING agonist that exhibits broad-spectrum antiviral activity. It functions by activating STING to induce the production of pro-inflammatory cytokines and activation of lymphocytes. This action inhibits the replication of Influenza A virus (IAV), SARS-CoV-2, and Human Rhinovirus (HRV), with an EC50 range of 11.8-199 nM.

diABZI-Mal is a STING agonist that activates the cGAS-STING pathway, leading to the production of cytokines such as type I interferon. It promotes the maturation of dendritic cells (DC) and effectively induces CD8+ T cell immune responses. Additionally, diABZI-Mal can inhibit tumor growth.

diABZI-a1 is an orthogonal STING agonist with an EC50 of 117 nM for inducing IFNβ in human PBMCs. This compound is applicable in the study of monogenic autoinflammatory diseases such as SAVI disease.

ABM5-OVA is a STING agonist-antigen conjugate created by linking diABZI-Mal with OVA(250-264). It effectively delivers antigens to the endoplasmic reticulum, ensuring colocalization of the antigen, STING, proteasome, and antigen transporter at the ER membrane. In numerous mouse models, ABM5-OVA induces a robust and lasting antigen-specific CD8+ T cell immune response, making it useful for vaccine adjuvant research.

diABZI-C2-NH2 is an agonist of the interferon gene STING that modulates STING-dependent type I interferon production and can be used to study STING-mediated diseases.